Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;14(6):101072.
doi: 10.1016/j.tranon.2021.101072. Epub 2021 Mar 18.

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

S N Feng  1 , X T Cen  1 , R Tan  1 , S S Wei  1 , L D Sun  2
Affiliations
Review

The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis

S N Feng et al. Transl Oncol. 2021 Jun.

Abstract

Background: Circulating tumor DNA (ctDNA) has been investigated as a potential prognostic biomarker to evaluate the therapeutic efficacy and disease progression in melanoma patients, yet results remain inconclusive. The purpose of this study was to illustrate the prognostic value of ctDNA in melanoma.

Objectives: To describe the clinical prognostic value of ctDNA for melanoma patients.

Methods: Searched for eligible articles from Pubmed, Web of Science and Embase. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the association between ctDNA at baseline or during treatment and overall survival (OS) and progression-free survival (PFS).

Results: A total of 9 articles were obtained, involving 617 melanoma patients. The pooled HRs revealed that compared with baseline undetectable ctDNA patients, detectable ctDNA was highly correlated with poor OS (HR 2.91, 95% CI: 2.22-3.82; p < 0.001) and PFS (HR 2.75, 95% CI: 1.98-3.83; p < 0.001). A meta-analysis of these adjusted HRs was performed and confirmed that ctDNA collected at baseline was associated with poorer OS/PFS (OS: HR 3.00, 95% CI 2.19-4.11, p < 0.001/PFS: HR 2.68, 95% CI 1.77-4.06, p < 0.001). During treatment, a significant association was shown between ctDNA and poorer OS/PFS (OS: HR 6.26, 95% CI 2.48-15.80, p < 0.001; PFS: HR 4.93, 95% CI 2.36-10.33, p < 0.001).

Conclusion: Investigation and application of ctDNA will improve "liquid biopsy" and play a role in early prediction, monitoring disease progression and precise adjusting treatment strategies in melanoma patients.

Keywords: Circulating tumor DNA; Melanoma; Meta-analysis; Prognostic value.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Image, graphical abstract
Graphical abstract
Fig 1
Fig. 1
PRISMA flowchart of the study. Selection process for study inclusion in the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).
Fig 2
Fig. 2
Forest plot adjusted and unadjusted hazard ratio (HR) for the correlation between ctDNA and OS in melanoma.
Fig 3
Fig. 3
Forest plot adjusted and unadjusted hazard ratio (HR) for the correlation between ctDNA and PFS in melanoma.
Fig 4
Fig. 4
Prognostic value of ctDNA in melanoma patients during treatment. (a) for OS; (b) for PFS.
Fig 5
Fig. 5
Cumulative meta-analysis for OS (a) and PFS (b), based on year of publication.
Fig 6
Fig. 6
Sensitivity analysis. (a) ctDNA for OS; (b) ctDNA for PFS.
Fig 7
Fig. 7
Begg's funnel plot and Egger's test to evaluate publication bias. (a) Begg's test for overall survival (OS); (b) Egger's test for OS; (c) Begg's test for progression-free survival (PFS); and (d) Egger's test for PFS.
See this image and copyright information in PMC

References

    1. DePeralta D.K., Boland G.M. Melanoma: advances in targeted therapy and molecular markers. Ann. Surg. Oncol. 2015;22:3451–3458. - PubMed
    1. Karagiannis P., Fittall M., Karagiannis S.N. Evaluating biomarkers in melanoma. Front. Oncol. 2014;4:383. - PMC - PubMed
    1. Schneegans S., Luck L., Besler K., Bluhm L., Stadler J.C., Staub J. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients. Mol. Oncol. 2020;14:1001–1015. - PMC - PubMed
    1. Francis G., Stein S. Circulating cell-free tumour DNA in the management of cancer. Int. J. Mol. Sci. 2015;16:14122–14142. - PMC - PubMed
    1. Oliveira K.C.S., Ramos I.B., Silva J.M.C., Barra W.F., Riggins G.J., Palande V. Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of cancer. Molecul. Cancer Res.: MCR. 2020;18:517–528. - PubMed

LinkOut - more resources